Adrenocortical carcinoma (ACC) is a rare cancer with an estimated
incidence of 1 to 2 patients per million people annually. About
50%–70% of adrenal cancers are functional; others instead have a
more silent clinical presentation and are detected only when they
grow to dimensions large enough to produce localised abdominal
symptoms. Kelechi K. Olu MD MSc, Vijay Rajendran MD and
Mohamed El Malt of Europital explain how the latest findings
in therapies and trials advocate for a greater focus on patients’
subgroups, with planned stratification of study subjects enrolled into
future clinical trials of ACC, might help determine the best course of
treatment for each patient.